Pfizer: positive study in cancer cachexia
(CercleFinance.com) - Pfizer presents positive data from a Phase 2 study of ponsegromab in patients with cancer cachexia.
The results will be presented today as a late-breaking presentation (LBA82) at the European Society for Medical Oncology (ESMO) 2024 Congress, and were published simultaneously in theNew England Journal of Medicine (NEJM).
The study met the primary endpoint of change from baseline in body weight for ponsegromab versus placebo for all ponsegromab doses tested, achieving a mean increase of 5.6% at the highest dose assessed at 12 weeks. Ponsegromab was generally considered safe and well-tolerated at all doses.
At the highest dose tested, improvements were observed compared to inclusion in symptoms of appetite and cachexia, physical activity and muscle mass.
Based on the positive Phase 2 results, registration-enabling studies will begin in 2025.
Cachexia is a common condition in cancer patients, associated with weight loss, functional decline and, ultimately, poor outcomes. Despite the number of people suffering from cachexia, there are no options available to help us treat patients, lead investigator Jeffrey Crawford, at Duke Cancer Institute said.
He added that this study showed us that those who received ponsegromab had improvements in body weight, muscle mass, quality of life and physical function. These results offer hope that a revolutionary targeted treatment is potentially on the horizon for our patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The results will be presented today as a late-breaking presentation (LBA82) at the European Society for Medical Oncology (ESMO) 2024 Congress, and were published simultaneously in theNew England Journal of Medicine (NEJM).
The study met the primary endpoint of change from baseline in body weight for ponsegromab versus placebo for all ponsegromab doses tested, achieving a mean increase of 5.6% at the highest dose assessed at 12 weeks. Ponsegromab was generally considered safe and well-tolerated at all doses.
At the highest dose tested, improvements were observed compared to inclusion in symptoms of appetite and cachexia, physical activity and muscle mass.
Based on the positive Phase 2 results, registration-enabling studies will begin in 2025.
Cachexia is a common condition in cancer patients, associated with weight loss, functional decline and, ultimately, poor outcomes. Despite the number of people suffering from cachexia, there are no options available to help us treat patients, lead investigator Jeffrey Crawford, at Duke Cancer Institute said.
He added that this study showed us that those who received ponsegromab had improvements in body weight, muscle mass, quality of life and physical function. These results offer hope that a revolutionary targeted treatment is potentially on the horizon for our patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.